INAB vs. HCWB, SGTX, ORPH, TTOO, ENLV, OTLK, VCXB, XFOR, CRDL, and KOD
Should you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include HCW Biologics (HCWB), Sigilon Therapeutics (SGTX), Orphazyme A/S (ORPH), T2 Biosystems (TTOO), Enlivex Therapeutics (ENLV), Outlook Therapeutics (OTLK), 10X Capital Venture Acquisition Corp. III (VCXB), X4 Pharmaceuticals (XFOR), Cardiol Therapeutics (CRDL), and Kodiak Sciences (KOD). These companies are all part of the "medical" sector.
HCW Biologics (NASDAQ:HCWB) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, community ranking, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.
HCW Biologics has higher revenue and earnings than IN8bio. HCW Biologics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.
IN8bio has a net margin of 0.00% compared to IN8bio's net margin of -697.53%. IN8bio's return on equity of -146.76% beat HCW Biologics' return on equity.
HCW Biologics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500.
IN8bio received 14 more outperform votes than HCW Biologics when rated by MarketBeat users. However, 100.00% of users gave HCW Biologics an outperform vote while only 68.97% of users gave IN8bio an outperform vote.
In the previous week, IN8bio had 6 more articles in the media than HCW Biologics. MarketBeat recorded 9 mentions for IN8bio and 3 mentions for HCW Biologics. IN8bio's average media sentiment score of 1.88 beat HCW Biologics' score of 0.08 indicating that HCW Biologics is being referred to more favorably in the media.
IN8bio has a consensus price target of $10.00, suggesting a potential upside of 852.38%. Given HCW Biologics' higher possible upside, analysts plainly believe IN8bio is more favorable than HCW Biologics.
3.0% of HCW Biologics shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 49.9% of HCW Biologics shares are owned by company insiders. Comparatively, 15.5% of IN8bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
HCW Biologics beats IN8bio on 9 of the 16 factors compared between the two stocks.
Get IN8bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
